Izernore (FR)
{name}
{subtitle}
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~38 mi. (Genève, Switzerland, +145 more cities)
facility
Hopitaux Universitaires de Geneve HUG ( Site 1706)
condition
Non-Small Cell Lung Carcinoma
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~38 mi. (Genève, Switzerland, +105 more cities)
facility
Hopitaux Universitaires de Geneve HUG. ( Site 1406)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib
drug type
targeted therapy
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
city
~38 mi. (Genève, Switzerland, +34 more cities)
facility
Hôpitaux Universitaires de Genève (HUG) ( Site 0335)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~44 mi. (Metz-Tessy, France, +158 more cities)
facility
Centre Hospitalier Annecy Genevois ( Site 0811)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~44 mi. (Pringy, France, +137 more cities)
facility
Centre Hospitalier Annecy Genevois ( Site 0361)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
city
~51 mi. (Quintaine, France, +84 more cities)
facility
Site FR33003
biomarker
CLDN18 Expression
condition
Pancreatic Adenocarcinoma
drug
gemcitabine, +2 more drugs
drug type
chemotherapy, +1 more type
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors
city
~62 mi. (Lyon 08, France, +29 more cities)
facility
Centre Leon Berard /ID# 218515
biomarker
ER Negative, +2 more biomarkers
condition
Breast Adenocarcinoma, +1 more condition
drug
ABBV-151, +1 more drug
drug type
immunotherapy, +1 more type